Who is sponsoring NCT00299507?

NCT00299507 is sponsored by Alcon Research.

What drugs are being tested in NCT00299507?

Interventions in NCT00299507: Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Vehicle.

What condition does NCT00299507 study?

NCT00299507 studies Macular Degeneration.

Is NCT00299507 still recruiting?

NCT00299507 is currently completed. Last updated 27 November 2012.

Last reviewed 2012-11-27 · How we verify

NCT00299507

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anecortave Acetate 15 mg Administered Every 3 Months Versus Anecortave Acetate 15 mg Administered Every 6 Months Versus Anecortave Acetate 30 mg Administered Every 6 Months in Patients With Exudative Age-Related Macular Degeneration (AMD)

Completed Phase 3 Last updated 27 November 2012

What this trial tests

Phase 3 trial testing Anecortave Acetate Sterile Suspension, 30 mg/mL in Macular Degeneration in 240 participants. Completed in 1 April 2008.

Timeline

1 March 2005

Primary endpoint
1 April 2008

1 April 2008

Quick facts

Lead sponsor	Alcon Research
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	240
Start date	1 March 2005
Primary completion	1 April 2008
Estimated completion	1 April 2008
Sites	1 location across United States

Drugs / interventions tested

Anecortave Acetate Sterile Suspension, 30 mg/mL — full drug profile →
Anecortave Acetate Sterile Suspension, 60 mg/mL — full drug profile →
Anecortave Acetate Vehicle

Conditions studied

Macular Degeneration — all drugs for Macular Degeneration →

Sponsor

Alcon Research — full company profile →

Who can join

50 and older, any sex, with Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Mean change in best-corrected visual acuity (BCVA) at Month 12 from baseline
Time frame: Month 12

Sponsor's own description

The purpose of this study was to evaluate the effect of the dose concentration and administration frequency of Anecortave Acetate (AA) on visual acuity (VA) and lesion size when administered by posterior juxtascleral depot (PJD) every 3 months (AA 15 mg) or 6 months (AA 15 mg, AA 30 mg) in patients with exudative age-related macular degeneration (AMD).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Recent Advances in Age-Related Macular Degeneration Therapies.
Fabre M, Mateo L, Lamaa D, Baillif S, et al · · 2022 · cited 68× · PMID 36014339 · DOI 10.3390/molecules27165089

Verify or expand the search:

Other recruiting trials for Macular Degeneration

Currently open trials in the same condition.

NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
NCT07085533 — Natural History Study of Inherited Retinal Diseases · recruiting
NCT06805474 — A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT · recruiting
NCT06779773 — A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy · recruiting
NCT06635148 — A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Se · Phase 2 · recruiting

Other Alcon Research trials

Trials by the same sponsor.

NCT06884202 — Evaluation of Delefilcon A Contact Lenses · NA · completed
NCT06784063 — Visual Performance With Clareon® Vivity® Intraocular Lenses (IOLs) · NA · completed
NCT06571656 — Evaluation of the Safety and Tolerability of Ocular Lubricants · NA · terminated
NCT06660290 — A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes · Phase 3 · completed
NCT06483113 — DAILIES TOTAL1® Soft Contact Lenses - Post-Market Clinical Follow-up Study · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00299507 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alcon Research
Last refreshed: 27 November 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00299507.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing